- Author: Namasivayam Ambalavanan, MD, MBBS; Chief Editor: Ted Rosenkrantz, MD more...
Bronchopulmonary dysplasia (see the image below) is a form of chronic lung disease that develops in preterm neonates treated with oxygen and positive-pressure ventilation. The pathogenesis of this condition remains complex and poorly understood; however various factors can not only injure small airways but also interfere with alveolarization (alveolar septation), leading to alveolar simplification with a reduction in the overall surface area for gas exchange. The developing pulmonary microvasculature can also be injured.
Signs and symptoms
Many infants born with bronchopulmonary dysplasia exhibit signs and symptoms of respiratory distress syndrome, including the following:
Increased respiratory effort (with retractions, nasal flaring, and grunting)
These infants are often extremely immature, have a very low birth weight, and have significant weight loss during the first 10 days of life. Their requirements for oxygen and ventilatory support often increase in the first 2 weeks of life. At weeks 2-4, oxygen supplementation, ventilator support, or both are often increased to maintain adequate ventilation and oxygenation.
See Clinical Presentation for more detail.
Laboratory studies used to evaluate and monitor infants with bronchopulmonary dysplasia include the following:
Arterial blood gas (ABG) levels: To assess for acidosis, hypercarbia, and hypoxia (with increased oxygen requirements)
Transcutaneous or end-tidal carbon dioxide levels: To evaluate trends, especially if the results are correlated with ABG levels
Pulmonary function tests
Continuously monitor oxygenation by using pulse oximetry because of frequent desaturations. In addition, routinely monitor blood pressure, as infants with bronchopulmonary dysplasia can also develop systemic hypertension.
The following radiologic studies may be used to evaluate infants with suspected bronchopulmonary dysplasia:
Chest radiography: To determine the severity of bronchopulmonary dysplasia; to differentiate bronchopulmonary dysplasia from atelectasis, pneumonia, and air leak syndrome; to demonstrate decreased lung volumes, areas of atelectasis and hyperinflation, pulmonary edema, and pulmonary interstitial emphysema
High-resolution chest computed tomography scanning
Chest magnetic resonance imaging
Biopsy of the lungs in preterm infants with bronchopulmonary dysplasia may reveal findings from the following 4 pathologic stages:
Acute lung injury
Obliterative fibroproliferative bronchiolitis
See Workup for more detail.
In most cases of bronchopulmonary dysplasia, respiratory distress syndrome is diagnosed and treated using the following:
Surfactant replacement with oxygen supplementation
Continuous positive airway pressure (CPAP)
Prenatal management in the pregnant mother to lower the risk bronchopulmonary dysplasia in the infant includes the following:
Treatment of the maternal inflammatory conditions, such as chorioamnionitis 
Treatment of maternal infection, such as Ureaplasma urealyticum infection 
Infants with bronchopulmonary dysplasia have increased energy requirements. The following nutritional strategies may help infants and their lungs grow and develop:
Administration of early parenteral nutrition
Maximization of protein, carbohydrates, fat, vitamins, and trace metals intake
Supplementation with antioxidant enzymes and vitamins A and E
Administration of free water (avoid fluid overload)
Protein and fat supplementation
Early enteral feeding of small amounts (even with umbilical lines in place), followed by slow, steady increases in volume: To optimize tolerance of feeds and nutritional support
The following medications are used in the management of bronchopulmonary dysplasia:
Diuretics (eg, furosemide)
Bronchodilators (eg, albuterol, caffeine citrate, theophylline, ipratropium bromide)
Corticosteroids (eg, dexamethasone)
Vitamins (eg, vitamin A)
Bronchopulmonary dysplasia (BPD) is a form of chronic lung disease that develops in preterm neonates treated with oxygen and positive-pressure ventilation (PPV).
Northway et al reported clinical, radiographic, and histologic changes in the lungs of preterm infants who had respiratory distress syndrome (RDS) and were treated with oxygen and mechanical ventilation.
Northway et al's original definition has been extensively modified over the last 4 decades. Bancalari et al’s definition involves ventilation criteria, an oxygen requirement at 28 days to maintain arterial oxygen tensions of more than 50 mm Hg, and abnormal findings on chest radiography. Shennan et al proposed that an additional need for supplemental oxygenation at 36 weeks' postmenstrual age may be the most accurate indicator of pulmonary outcome; this criterion decreased the large number of relatively healthy preterm infants Bancalari and others included in their definitions.
Jobe and Bancalari summarized proceedings of a National Institute of Health consensus conference on bronchopulmonary dysplasia. Investigators from the National Institute of Child Health and Human Development (NICHD) have validated their recommendations. This group improved the definition of bronchopulmonary dysplasia and attempted to assign a severity score based on oxygen requirements and the need for respiratory support. However, physicians and institutions may set different standards for oxygen requirements and for target ranges for oxygen saturation. This variation in practice may notably influence the incidence and severity of bronchopulmonary dysplasia in a particular neonatal ICU (NICU).
To overcome this limitation due to subjectivity in "need for oxygen," Walsh et al recently developed a physiologic definition of bronchopulmonary dysplasia. According to this definition, at 35-37 weeks' postmenstrual age, infants treated with mechanical ventilation, continuous positive airway pressure (CPAP), or supplemental oxygen concentration of 30% and oxygen saturations of 90-96% were diagnosed with bronchopulmonary dysplasia without additional testing. Infants with supplemental oxygen concentrations of 30% at rest with oxygen saturations of 90-96% or supplemental oxygen concentrations of 30% with oxygen saturations of more than 96% underwent a timed stepwise reduction to room air.
For infants receiving oxygen by hood, oxygen was weaned in 2% increments. For infants receiving oxygen by nasal cannulae, flow was initially weaned in increments (for flow of 1–2, step down 0.5 liters per minute [lpm]; for flow 0.1-0.99 lpm, step down 0.1 lpm), and then the oxygen concentration was reduced in increments of 20% to room air. Cannulae were removed from the nares for the remainder of the challenge. Oxygen that was given only during feedings was not included for the purposes of eligibility. Those who failed the reduction were diagnosed with bronchopulmonary dysplasia.
No bronchopulmonary dysplasia was defined by requiring treatment with room air with oxygen saturation of more than 90% or passing a timed, continuously monitored oxygen-reduction test. The physiologic definition of bronchopulmonary dysplasia reduced the overall rate of bronchopulmonary dysplasia and reduced the variation among centers. The physiologic definition may facilitate the measurement of bronchopulmonary dysplasia as an outcome in clinical trials and the comparison between and within centers over time.
Recently, models have been developed for predicting the probability of BPD at specific postnatal time points using readily available clinical data. Prediction improved with advancing postnatal age, increasing from a C statistic (area under the curve) of 0.79 on day 1 to a maximum of 0.85 on day 28. On postnatal days 1 and 3, gestational age best improved outcome prediction, while type of respiratory support was most important on postnatal days 7, 14, 21, and 28.
The pathogenesis of bronchopulmonary dysplasia remains complex and poorly understood. Bronchopulmonary dysplasia results from various factors that can injure small airways and that can interfere with alveolarization (alveolar septation), leading to alveolar simplification with a reduction in the overall surface area for gas exchange. The developing pulmonary microvasculature can also be injured. Alveolar and lung vascular development are intimately related, and injury to one may impair development of the other. Damage to the lung during a critical stage of lung growth can result in clinically significant pulmonary dysfunction.
Premature birth and subsequent events (eg, exposure to oxygen, mechanical ventilation, inflammatory agents, infection) likely shifts the balance from lung development consisting of lung alveolar and vascular growth to one of premature maturation, which is associated with an arrest in development and a loss of future gas exchange area; however, alveolar maturation might facilitate gas exchange in the short-term.
Infants with severe bronchopulmonary dysplasia are often extremely immature and have very low birth weight, although term infants with severe respiratory failure are also at increased risk. Bronchopulmonary dysplasia is uncommon in infants with a birth weight of more than 1250 g and in infants who were born at more than 30 weeks' gestation. Overall, about one fourth of infants who weigh less than 1500 g are diagnosed with bronchopulmonary dysplasia.
Antenatal glucocorticosteroids, early surfactant therapy, and gentle modalities of ventilation have minimized the severity of lung injury, particularly in relatively mature infants. However, improved survival has increased the prevalence of bronchopulmonary dysplasia, especially in small infants who may have been exposed to in utero infection (eg, chorioamnionitis).
Several trials of surfactants revealed that incidences of bronchopulmonary dysplasia widely vary, from 17-57%. No substantial difference between placebo-treated and surfactant-treated survivors has been reported. Kresch and Clive performed a meta-analysis of surfactant-replacement therapy for infants weighing less than 2 kg. Infants receiving modified natural surfactant had improved survival without bronchopulmonary dysplasia. Van Marter and associates described the wide variation in the prevalence of bronchopulmonary dysplasia in different NICUs using various ventilatory strategies. This variation has also been noted among sites in the Vermont Oxford Network (VON) and in the NICHD research network, suggesting that differences in patient populations and clinical practices may directly affect outcomes.
Studies similar to those in the United States have been conducted to compare rates of bronchopulmonary dysplasia in different NICUs in Europe. Results have been similar despite the relatively homogeneous population.
Since the introduction of surfactant replacement, survival of the most immature infants has improved. However, the stable 25-50% survival rates in preterm infants at 23-24 weeks' gestation likely reflect the lack of alveolarization and vascular development. Survival and morbidity improved in infants older than 24 weeks' gestation after the widespread administration of antenatal corticosteroids was introduced in 1994.
Along with other advances in technology and an improved understanding of neonatal physiology, infants with bronchopulmonary dysplasia appear to have milder disease today than in years past.
Infants with severe bronchopulmonary dysplasia remain at high risk for pulmonary morbidity and mortality during the first 2 years of life. Infants with bronchopulmonary dysplasia are at risk for repeated pulmonary infections and asthma requiring repeated hospital admissions and office visits.
Abnormal long-term neurodevelopmental outcome, muscular development, slow growth, and chronic pulmonary morbidity are common in infants with bronchopulmonary dysplasia. Whether abnormal neurodevelopmental outcomes are directly related to bronchopulmonary dysplasia or to the patients' marked immaturity and disease severity is hard to determine.
Compared with white infants, African American infants generally have a lower incidence of severe bronchopulmonary dysplasia, although the combined rate of bronchopulmonary dysplasia and death is often similar in persons of different races.
Male infants with bronchopulmonary dysplasia tend to have more severe disease and worse neurodevelopmental outcome.
Bronchopulmonary dysplasia is most common in the most immature neonates born at 22-30 weeks' gestational age. These patients frequently weigh less than 1000 g at birth.
Hartling L, Liang Y, Lacaze-Masmonteil T. Chorioamnionitis as a risk factor for bronchopulmonary dysplasia: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2012 Jan. 97(1):F8-F17. [Medline].
Viscardi RM, Muhumuza CK, Rodriguez A, et al. Inflammatory markers in intrauterine and fetal blood and cerebrospinal fluid compartments are associated with adverse pulmonary and neurologic outcomes in preterm infants. Pediatr Res. 55(6):1009-17. [Medline].
Northway WH Jr, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med. 1967 Feb 16. 276(7):357-68. [Medline].
Bancalari E, Abdenour GE, Feller R, Gannon J. Bronchopulmonary dysplasia: clinical presentation. J Pediatr. 1979 Nov. 95(5 Pt 2):819-23. [Medline].
Shennan AT, Dunn MS, Ohlsson A, et al. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics. 1988 Oct. 82(4):527-32. [Medline].
Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001 Jun. 163(7):1723-9. [Medline].
Walsh MC, Yao Q, Gettner P, et al. Impact of a physiologic definition on bronchopulmonary dysplasia rates. Pediatrics. Nov 2004. 114:1305-11. [Medline].
Laughon MM, Langer JC, Bose CL, et al. Prediction of bronchopulmonary dysplasia by postnatal age in extremely premature infants. Am J Respir Crit Care Med. 2011 Jun 15. 183(12):1715-22. [Medline]. [Full Text].
Ambalavanan N, Carlo WA. Bronchopulmonary dysplasia: new insights. Clin Perinatol. Sept 2004. 31:613-28. [Medline].
Kresch MJ, Clive JM. Meta-analyses of surfactant replacement therapy of infants with birth weights less than 2000 grams. J Perinatol. 1998 Jul-Aug. 18(4):276-83. [Medline].
Van Marter LJ, Allred EN, Pagano M, et al. Do clinical markers of barotrauma and oxygen toxicity explain interhospital variation in rates of chronic lung disease? The Neonatology Committee for the Developmental Network. Pediatrics. 2000 Jun. 105(6):1194-201. [Medline].
Jobe AJ. The new BPD: an arrest of lung development. Pediatr Res. 1999 Dec. 46(6):641-3. [Medline].
Kim BI, Lee HE, Choi CW, et al. Increase in cord blood soluble E-selectin and tracheal aspirate neutrophils at birth and the development of new bronchopulmonary dysplasia. J Perinat Med. 32(3):282-7. [Medline].
Borghesi A, Massa M, Campanelli R, et al. Circulating endothelial progenitor cells in preterm infants with bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2009 Sep 15. 180(6):540-6. [Medline].
SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal ResearchNetwork, Carlo WA, Finer NN, Walsh MC, Rich W, Gantz MG, et al. Target ranges of oxygen saturation in extremelypreterm infants. N Engl J Med. May 2010. 362(21):1959-69. [Medline]. [Full Text].
Oh W, Poindexter BB, Perritt R, Lemons JA, Bauer CR, Ehrenkranz RA. Association between fluid intake and weight loss during the first ten days of life and risk of bronchopulmonary dysplasia in extremely low birth weight infants. J Pediatr. 2005 Dec. 147(6):786-90. [Medline].
Walsh MC, Szefler S, Davis J, et al. Summary proceedings from the bronchopulmonary dysplasia group. Pediatrics. 2006 Mar. 117(3 Pt 2):S52-6. [Medline].
Hoffman DJ, Gerdes JS, Abbasi S. Pulmonary function and electrolyte balance following spironolactone treatment in preterm infants with chronic lung disease: a double-blind, placebo-controlled, randomized trial. J Perinatol. 2000 Jan-Feb. 20(1):41-5. [Medline].
Schmidt B, Roberts RS, Davis P, et al. Caffeine therapy for apnea of prematurity. N Engl J Med. 2006 May 18. 354(20):2112-21. [Medline].
Papile LA, Tyson JE, Stoll BJ, et al. A multicenter trial of two dexamethasone regimens in ventilator-dependent premature infants. N Engl J Med. 1998 Apr 16. 338(16):1112-8. [Medline].
[Guideline] AAP. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Pediatrics. 1998 Nov. 102(5):1211-6. [Medline].
[Guideline] AAP. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics. 2003 Dec. 112(6 Pt 1):1442-6. [Medline].
Hakulinen AL, Heinonen K, Lansimies E, Kiekara O. Pulmonary function and respiratory morbidity in school-age children born prematurely and ventilated for neonatal respiratory insufficiency. Pediatr Pulmonol. 1990. 8(4):226-32. [Medline].
Northway WH Jr. Bronchopulmonary dysplasia: twenty-five years later. Pediatrics. 1992 May. 89(5 Pt 1):969-73. [Medline].
Bader D, Ramos AD, Lew CD, et al. Childhood sequelae of infant lung disease: exercise and pulmonary function abnormalities after bronchopulmonary dysplasia. J Pediatr. 1987 May. 110(5):693-9. [Medline].
Blayney M, Kerem E, Whyte H, O'Brodovich H. Bronchopulmonary dysplasia: improvement in lung function between 7 and 10 years of age. J Pediatr. 1991 Feb. 118(2):201-6. [Medline].
Ambalavanan N, Tyson JE, Kennedy KA, et al. Vitamin A supplementation for extremely low birth weight infants: outcome at 18 to 22 months. Pediatrics. 2005 Mar. 115(3):e249-54. [Medline].
Bourbia A, Cruz MA, Rozycki HJ. NF-kappaB in tracheal lavage fluid from intubated premature infants: association with inflammation, oxygen, and outcome. Arch Dis Child Fetal Neonatal Ed. 2006 Jan. 91(1):F36-9. [Medline].
Brundage KL, Mohsini KG, Froese AB, Fisher JT. Bronchodilator response to ipratropium bromide in infants with bronchopulmonary dysplasia. Am Rev Respir Dis. 1990 Nov. 142(5):1137-42. [Medline].
Douglas D. Hydrocortisone seems safe in infantile bronchopulmonary dysplasia. June 05, 2013. Medscape Medical News. Available at http://www.medscape.com/viewarticle/805393. Accessed: June 10, 2013.
Ehrenkranz RA, Walsh MC, Vohr BR, et al. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics. 2005 Dec. 116(6):1353-60. [Medline].
Jobe AH. Antenatal associations with lung maturation and infection. J Perinatol. 2005 May. 25 Suppl 2:S31-5. [Medline].
Kakkera DK, Siddiq MM, Parton LA. Interleukin-1 balance in the lungs of preterm infants who develop bronchopulmonary dysplasia. Biol Neonate. 2005. 87(2):82-90. [Medline].
Kallapur SG, Jobe AH. Contribution of inflammation to lung injury and development. Arch Dis Child Fetal Neonatal Ed. 2006 Mar. 91(2):F132-5. [Medline].
Kersbergen KJ, de Vries LS, van Kooij BJ, Išgum I, Rademaker KJ, van Bel F, et al. Hydrocortisone Treatment for Bronchopulmonary Dysplasia and Brain Volumes in Preterm Infants. J Pediatr. 2013 May 21. [Medline].
Korhonen P, Hyodynmaa E, Lautamatti V, et al. Cardiovascular findings in very low birthweight schoolchildren with and without bronchopulmonary dysplasia. Early Hum Dev. 2005 Jun. 81(6):497-505. [Medline].
Schelonka RL, Katz B, Waites KB, Benjamin DK Jr. Critical appraisal of the role of Ureaplasma in the development of bronchopulmonary dysplasia with metaanalytic techniques. Pediatr Infect Dis J. 2005 Dec. 24(12):1033-9. [Medline].
Smith VC, Zupancic JA, McCormick MC. Trends in severe bronchopulmonary dysplasia rates between 1994 and 2002. J Pediatr. 2005 Apr. 146(4):469-73. [Medline].
Stoelhorst GMS, Rijken M, Martens S, et al. Changes in Neonatology: Comparison of two cohorts of very preterm infants (Gestational Age 11111111111111111Pediatrics</i>. 2005. 115:396-405.